J Goodwin to Androgen Antagonists
This is a "connection" page, showing publications J Goodwin has written about Androgen Antagonists.
Connection Strength
1.073
-
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007 Dec 01; 25(34):5359-65.
Score: 0.277
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006 Jun 21; 98(12):839-45.
Score: 0.251
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006 Feb 27; 166(4):465-71.
Score: 0.246
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 Jan 13; 352(2):154-64.
Score: 0.227
-
Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008 Jun; 112(11):2456-66.
Score: 0.072